Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03441555
Recruitment Status : Active, not recruiting
First Posted : February 22, 2018
Last Update Posted : May 19, 2020
Sponsor:
Collaborator:
Sumitomo Dainippon Pharma Oncology, Inc
Information provided by (Responsible Party):
AbbVie

Brief Summary:
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Drug: Venetoclax Drug: Alvocidib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : May 30, 2018
Estimated Primary Completion Date : July 21, 2021
Estimated Study Completion Date : July 21, 2021


Arm Intervention/treatment
Experimental: Venetoclax + Alvocidib
Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
Drug: Venetoclax
tablet, oral
Other Name: ABT-199

Drug: Alvocidib
Intravenous
Other Name: Flavopiridol




Primary Outcome Measures :
  1. Tmax of venetoclax [ Time Frame: Approximately 32 days after first dose of study drug ]
    Time to maximum plasma concentration (Tmax) of venetoclax

  2. Clearance of Alvocidib [ Time Frame: Approximately 32 days after first dose of study drug ]
    Clearance (CL) of alvocidib

  3. AUC0-∞ of Alvocidib [ Time Frame: Approximately 32 days after first dose of study drug ]
    Area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) post-dose of alvocidib

  4. Cmax of Venetoclax [ Time Frame: Approximately 32 days after first dose of study drug ]
    Maximum plasma concentration (Cmax) of venetoclax

  5. Half-life (t1/2) of Alvocidib [ Time Frame: Approximately 32 days after first dose of study drug ]
    Half-life (t1/2) of alvocidib

  6. AUC0-24 Post-dose of Venetoclax [ Time Frame: Approximately 32 days after first dose of study drug ]
    Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.

  7. Cmax of Alvocidib [ Time Frame: Approximately 32 days after first dose of study drug ]
    Maximum plasma concentration (Cmax) of alvocidib.

  8. AUCt Post-dose of Alvocidib [ Time Frame: Approximately 32 days after first dose of study drug ]
    Area under the plasma concentration-time curve from time zero to time t (AUCt) post-dose alvocidib.

  9. Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib [ Time Frame: Minimum first cycle of dosing (up to 28 days) ]
    RPTD will be determined using available safety and pharmacokinetics data upon completion of the dose escalation phase.


Secondary Outcome Measures :
  1. Complete Response (CR) Rate [ Time Frame: Up to approximately 8 months ]
    CR is defined as the proportion of participants with documented complete response (CR) based on International Working Group (IWG) criteria.

  2. Combined CR Rate [ Time Frame: Up to approximately 8 months ]
    Combined CR rate is defined as CR + CRi (CR with incomplete blood count recovery) based on IWG criteria.

  3. Objective Response Rate (ORR) [ Time Frame: Up to approximately 18 months ]
    ORR is defined as the proportion of participants with documented partial response (PR) or better based on IWG criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have adequate coagulation, hematology, kidney, and liver function, per protocol.
  • Diagnosis of relapsed or refractory (R/R) acute myeloid leukemia (AML)
  • Meet the following disease activity criteria:
  • an established, confirmed diagnosis of AML by World Health Organization criteria excluding acute promyelocytic leukemia (APL)-M3; and
  • an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  • If male participant is sexually active, he must agree from day 1 through 6 months after the last dose of alvocidib or 90 days after the last dose of venetoclax, whichever is longer, to practice the protocol-specified protection.

Exclusion Criteria:

  • History of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment such as non-melanoma skin cancer, cervical intraepithelial neoplasia, or prostate cancer in situ.
  • Prior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.
  • History of previous enrollment in Studies NCT02993523 or NCT03069352.
  • History of exposure to alvocidib or any other cyclin-dependent kinase 9 (CDK9) inhibitor.
  • History of Tumor Lysis Syndrome (TLS) due to previous exposure to venetoclax.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03441555


Locations
Layout table for location information
United States, California
USC Norris Cancer Center /ID# 170844
Los Angeles, California, United States, 90033
UC Irvine /ID# 201093
Orange, California, United States, 92868
UC Davis Comprehensive Cancer Center - Main /ID# 170799
Sacramento, California, United States, 95817
United States, Florida
Sylvester Comprehensive Cancer /ID# 170761
Miami, Florida, United States, 33136-1002
United States, Indiana
Indiana Blood & Marrow Transpl /ID# 170793
Indianapolis, Indiana, United States, 46237
United States, New York
NYU Langone Medical Center /ID# 201559
New York, New York, United States, 10016-6402
Weill Cornell Medical College /ID# 170800
New York, New York, United States, 10021
United States, North Carolina
Duke University Medical Center /ID# 170842
Durham, North Carolina, United States, 27710-3000
United States, Pennsylvania
University of Pittsburgh Medic /ID# 170790
Pittsburgh, Pennsylvania, United States, 15261
Germany
Universitaetsklinikum Dresden /ID# 168636
Dresden, Germany, 01307
Univ Klinik Eppendorf Hamburg /ID# 168633
Hamburg, Germany, 20246
United Kingdom
University Hospital of Wales /ID# 202302
Cardiff, United Kingdom, CF14 4EN
Ninewells Hospital /ID# 202304
Dundee, United Kingdom, DD1 9SY
St. James University Hospital /ID# 202303
Leeds, United Kingdom, LS9 7TF
Sponsors and Collaborators
AbbVie
Sumitomo Dainippon Pharma Oncology, Inc
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
Additional Information:
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03441555    
Other Study ID Numbers: M16-186
2017-002531-42 ( EudraCT Number )
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: May 19, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Cancer
Acute Myeloid Leukemia (AML)
relapsed Acute Myeloid Leukemia
refractory Acute Myeloid Leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Venetoclax
Alvocidib
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action